|
× |
 |
Article: Highlights in breast cancer |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Highlights in digestive oncology |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: INTRODUCTION |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: INTRODUCTION |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Highlights in squamous cell carcinoma of the head and neck |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Highlights in melanoma |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer |
€2.42 |
|
€2.42 (incl. VAT) |
|
|
Top
